OPKO Health (NASDAQ:OPK) Raised to Hold at StockNews.com

OPKO Health (NASDAQ:OPK - Get Free Report) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Wednesday.

A number of other equities analysts also recently issued reports on the company. Piper Sandler reissued an "overweight" rating and set a $3.00 target price on shares of OPKO Health in a research note on Tuesday, September 17th. Barrington Research reaffirmed an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th.

OPKO Health Stock Performance

OPK traded down $0.05 on Wednesday, hitting $1.56. 3,137,497 shares of the company traded hands, compared to its average volume of 6,789,538. OPKO Health has a 12-month low of $0.85 and a 12-month high of $1.76. The company has a 50 day moving average of $1.54 and a 200-day moving average of $1.48. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $1.06 billion, a PE ratio of -8.21 and a beta of 1.62.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 125,000 shares of the firm's stock in a transaction dated Friday, December 13th. The stock was acquired at an average price of $1.59 per share, for a total transaction of $198,750.00. Following the acquisition, the chief executive officer now owns 212,536,477 shares of the company's stock, valued at $337,932,998.43. This trade represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders purchased 1,304,255 shares of company stock worth $2,024,605. 47.26% of the stock is owned by company insiders.

Institutional Trading of OPKO Health

Several large investors have recently added to or reduced their stakes in OPK. Rubric Capital Management LP grew its position in OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock valued at $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company's stock valued at $2,227,000 after purchasing an additional 876,272 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in OPKO Health during the 2nd quarter valued at $592,000. Y.D. More Investments Ltd purchased a new stake in OPKO Health during the 2nd quarter worth $1,840,000. Finally, BNP Paribas Financial Markets lifted its holdings in OPKO Health by 736.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock worth $368,000 after buying an additional 217,450 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.